Anticipatory guidance in type 2 diabetes to improve disease management; next steps after basal insulin

References

• Stratton IM , Adler AI , Neil HA , et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412.
   PubMed Web of Science ®Google Scholar
• Holman RR , Paul SK , Bethel MA , et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association . Standards of medical care in diabetes — 2018. Diabetes Care. 2018;41(Supplement 1):S1–S155.
   PubMed Web of Science ®Google Scholar
• Garber AJ , Abrahamson MJ , Barzilay JI , et al.; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE) . Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2018 Executive Summary. Endocr Pract. 2018;24(1):91–120.
   PubMed Web of Science ®Google Scholar
• Stark Casagrande S , Fradkin JE , Saydah SH , et al. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010. Diabetes Care. 2013;36(8):2271–2279.
   PubMed Web of Science ®Google Scholar
• Schatz D. 2016 presidential address: diabetes at 212°—Confronting the Invisible Disease. Diabetes Care. 2016;39(10):1657–1663.
   PubMed Web of Science ®Google Scholar
• Pimouguet C , Le Goff M , Thiébaut R , et al. Effectiveness of disease-management programs for improving diabetes care: a meta-analysis. CMAJ. 2011;183(2):E115–127.
   PubMed Web of Science ®Google Scholar
• Chrvala CA , Sherr D , Lipman RD . Diabetes self-management education for adults with type 2 diabetes mellitus: a systematic review of the effect on glycemic control. Patient Educ Couns. 2016;99(6):926–943.
   PubMed Web of Science ®Google Scholar
• Grossoehme DH , Filigno SS , Bishop M . Parent routines for managing cystic fibrosis in children. J Clin Psychol Med Settings. 2014;21(2):125–135.
   PubMed Web of Science ®Google Scholar
• Butow P , Palmer S , Pai A , et al. Review of adherence-related issues in adolescents and young adults with cancer. J Clin Oncol. 2010;28(32):4800–4809.
   PubMed Web of Science ®Google Scholar
• Comeaux SJ , Jaser SS . Autonomy and insulin in adolescents with type 1 diabetes. Pediatr Diabetes. 2010;11(7):498–504.
   PubMed Web of Science ®Google Scholar
• Anderson BJ . Can we break down barriers to excellent diabetes healthcare for teenagers with diabetes? Diabetes Manage. 2012;2(6):471–473.
   Google Scholar
• Lyons SK , Libman IM , Sperling MA . Clinical review: diabetes in the adolescent: transitional issues. J Clin Endocrinol Metab. 2013;98(12):4639–4645.
   PubMed Web of Science ®Google Scholar
• Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Wherrett D , Huot C , Mitchell B , et al. Type 1 diabetes in children and adolescents. Can J Diabetes. 2013;37(Suppl 1):S153–162.
   PubMedGoogle Scholar
• Syverson EP , McCarter R , He J , et al. Adolescents’ perceptions of transition importance, readiness, and likelihood of future success: the role of anticipatory guidance. Clin Pediatr (Phila). 2016;55(11):1020–1025.
   PubMed Web of Science ®Google Scholar
• Corathers SD , Kichler JC , Fino NF , et al. High health satisfaction among emerging adults with diabetes: factors predicting resilience. Health Psychol. 2017;36(3):206–214.
   PubMed Web of Science ®Google Scholar
• Ross SA . Breaking down patient and physician barriers to optimize glycemic control in type 2 diabetes. Am J Med. 2013;126(9 Suppl 1):S38–48.
   PubMed Web of Science ®Google Scholar
• Aujoulat I , Jacquemin P , Rietzschel E , et al. Factors associated with clinical inertia: an integrative review. Adv Med Educ Pract. 2014;5:141–147.
   PubMedGoogle Scholar
• Blonde L , Aschner P , Bailey C , et al. Global partnership for effective diabetes management. Gaps and barriers in the control of blood glucose in people with type 2 diabetes. Diab Vasc Dis Res. 2017;14(3):172–183.
   PubMed Web of Science ®Google Scholar
• Khunti K , Nikolajsen A , Thorsted BL , et al. Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin. Diabetes Obes Metab. 2016;18(4):401–409.
   PubMed Web of Science ®Google Scholar
• Khunti K , Millar-Jones D . Clinical inertia to insulin initiation and intensification in the UK: a focused literature review. Prim Care Diabetes. 2017;11(1):3–12.
   PubMed Web of Science ®Google Scholar
• Peyrot M , Barnett AH , Meneghini LF , et al. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy Study. Diabet Med. 2012;29(5):682–689.
   PubMed Web of Science ®Google Scholar
• Ahrén B . Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Manag. 2013;9:155–163.
   PubMedGoogle Scholar
• Kruger DF , LaRue S , Estepa P . Recognition of and steps to mitigate anxiety and fear of pain in injectable diabetes treatment. Diabetes Metab Syndr Obes. 2015;8:49–56.
   PubMed Web of Science ®Google Scholar
• Xie L , Wei W , Pan C , et al. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies. J Med Econ. 2013;16(9):1137–1145.
   PubMedGoogle Scholar
• Wang L , Wei W , Miao R , et al. Real-world outcomes of US employees with type 2 diabetes mellitus treated with insulin glargine or neutral protamine Hagedorn insulin: a comparative retrospective database study. BMJ Open. 2013;3(4):e002348.
   PubMed Web of Science ®Google Scholar
• Dalal MR , Kazemi MR , Ye F . Hypoglycemia in patients with type 2 diabetes newly initiated on basal insulin in the US in a community setting: impact on treatment discontinuation and hospitalization. Curr Med Res Opin. 2017;33(2):209–214.
   PubMed Web of Science ®Google Scholar
• Fonseca V , Chou E , Chung HW , et al. Economic burden of hypoglycemia with basal insulin in type 2 diabetes. Am J Manag Care. 2017;23(2):114–122.
   PubMed Web of Science ®Google Scholar
• Wei W , Buysman E , Grabner M , et al. A real-world study of treatment patterns and outcomes in US managed-care patients with type 2 diabetes initiating injectable therapies. Diabetes Obes Metab. 2017;19(3):375–386.
   PubMed Web of Science ®Google Scholar
• Levin PA , Zhou S , Gill J , et al. Health outcomes associated with initiation of basal insulin after 1, 2, or ≥ 3 oral antidiabetes drug(s) among managed care patients with type 2 diabetes. J Manag Care Spec Pharm. 2015;21(12):1172–1181.
   PubMed Web of Science ®Google Scholar
• Elliott L , Fidler C , Ditchfield A , et al. Hypoglycemia event rates: a comparison between real-world data and randomized controlled trial populations in insulin-treated diabetes. Diabetes Ther. 2016;7(1):45–60.
   PubMed Web of Science ®Google Scholar
• Seaquist ER , Anderson J , Childs B , et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36(5):1384–1395.
   PubMed Web of Science ®Google Scholar
• LaSalle JR , Berria R . Insulin therapy in type 2 diabetes mellitus: a practical approach for primary care physicians and other health care professionals. J Am Osteopath Assoc. 2013;113(2):152–162.
   PubMedGoogle Scholar
• Monnier L , Colette C . Contributions of fasting and postprandial glucose to hemoglobin A1c. Endocr Pract. 2006;12(Suppl 1):42–46.
   PubMedGoogle Scholar
• Monnier L , Lapinski H , Colette C . Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26(3):881–885.
   PubMed Web of Science ®Google Scholar
• Riddle MC . Basal glucose can be controlled, but the prandial problem persists—it’s the next target! Diabetes Care. 2017;40(3):291–300.
   PubMed Web of Science ®Google Scholar
• Cavalot F , Pagliarino A , Valle M , et al. Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study. Diabetes Care. 2011;34(10):2237–2243.
   PubMed Web of Science ®Google Scholar
• Takao T , Suka M , Yanagisawa H , et al. Impact of postprandial hyperglycemia at clinic visits on the incidence of cardiovascular events and all-cause mortality in patients with type 2 diabetes. J Diabetes Investig. 2017;8(4):600–608.
   PubMed Web of Science ®Google Scholar
• Shaefer C , Traylor L , Gao L , et al. Exploratory study of a dose-response curve for basal insulin. Poster presented at the 75th Scientific Sessions of the American Diabetes Association; 2015 June 5–9, Boston (MA).
   Google Scholar
• Rosenstock J , Davies M , Home PD , et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetologia. 2008;51(3):408–416.
   PubMed Web of Science ®Google Scholar
• Swinnen SG , Dain MP , Aronson R , et al. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care. 2010;33(6):1176–1178.
   PubMed Web of Science ®Google Scholar
• Meneghini L , Kesavadev J , Demissie M , et al. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15(8):729–736.
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H , Dressler A , Ziemen M . HOE 901/300s Study Group . Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care. 2000;23(8):1130–1136.
   PubMed Web of Science ®Google Scholar
• Riddle MC , Rosenstock J , Gerich J ; Insulin Glargine 4002 Study Investigators . The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080–3086.
   PubMed Web of Science ®Google Scholar
• Zinman B , Philis-Tsimikas A , Cariou B , et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012;35(12):2464–2471.
   PubMed Web of Science ®Google Scholar
• Pan C , Gross JL , Yang W , et al. A multinational, randomized, open-label, treat-to-target trial comparing insulin degludec and insulin glargine in insulin-naïve patients with type 2 diabetes mellitus. Drugs R D. 2016;16(2):239–249.
   PubMed Web of Science ®Google Scholar
• Meneghini L , Atkin SL , Gough SC , et al.; NN1250-3668 (BEGIN FLEX) Trial Investigators . The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care. 2013;36(4):858–864.
   PubMed Web of Science ®Google Scholar
• Gough SC , Bhargava A , Jain R , et al. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care. 2013;36(9):2536–2542.
   PubMed Web of Science ®Google Scholar
• Philis-Tsimikas A , Brod M , Niemeyer M , et al. Insulin degludec once-daily in type 2 diabetes: simple or step-wise titration (BEGIN: oncesimple use). Adv Ther. 2013;30(6):607–622.
   PubMed Web of Science ®Google Scholar
• Rodbard HW , Cariou B , Zinman B , et al.; BEGIN Once Long trial investigators . Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial. Diabet Med. 2013;30(11):1298–1304.
   PubMed Web of Science ®Google Scholar
• Bolli GB , Riddle MC , Bergenstal RM , et al.; on behalf of the EDITION 3 study investigators . New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab. 2015;17(4):386–394.
   PubMed Web of Science ®Google Scholar
• Jakobsen M , Dalsgaard M , Hørmann M , et al. Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients. BMC Endocr Disord. 2012;12:21.
   PubMed Web of Science ®Google Scholar
• Borah BJ , Darkow T , Bouchard J , et al. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes. Clin Ther. 2009;31(3):623–631.
   PubMed Web of Science ®Google Scholar
• McAdam-Marx C , Yu J , Bouchard J , et al. Comparison of daily insulin dose and other antidiabetic medications usage for type 2 diabetes patients treated with an analog basal insulin. Curr Med Res Opin. 2010;26(1):191–201.
   PubMed Web of Science ®Google Scholar
• Patton SR . Adherence to glycemic monitoring in diabetes. J Diabetes Sci Technol. 2015;9(3):668–675.
   PubMedGoogle Scholar
• Powers MA , Bardsley J , Cypress M , et al. Diabetes self-management education and support in type 2 diabetes: a joint position statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. Diabetes Care. 2015;38(7):1372–1382.
   PubMed Web of Science ®Google Scholar
• Owens DR . Stepwise intensification of insulin therapy in type 2 diabetes management–exploring the concept of the basal-plus approach in clinical practice. Diabet Med. 2013;30(3):276–288.
   PubMed Web of Science ®Google Scholar
• Riddle MC , Rosenstock J , Vlajnic A , et al. Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections. Diabetes Obes Metab. 2014;16(5):396–402.
   PubMed Web of Science ®Google Scholar
• Downie M , Kilov G , Wong J . Initiation and intensification strategies in type 2 diabetes management: a comparison of basal plus and premix regimens. Diabetes Ther. 2016;7(4):641–657.
   PubMed Web of Science ®Google Scholar
• Balena R , Hensley IE , Miller S , et al. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab. 2013;15(6):485–502.
   PubMed Web of Science ®Google Scholar
• Rosenstock J , Fonseca VA , Gross JL , et al.; Harmony 6 Study Group . Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. Diabetes Care. 2014;37(8):2317–2325.
   PubMed Web of Science ®Google Scholar
• Prasad-Reddy L , Isaacs D . A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015;4:212283.
   PubMedGoogle Scholar
• Soliqua . Prescribing information (PI). [cited 2017 Nov 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208673s000lbl.pdf
   Google Scholar
• Suliqua . Summary of Product Characteristics (SPC). [cited 2017 Jul 14]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004243/WC500224673.pdf
   Google Scholar
• Xultophy 100/3.6 . Prescribing Information (PI). [cited 2017 Jul 14]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208583s000lbl.pdf
   Google Scholar
• Xultophy . Summary of Product Characteristics (SPC). [cited 2017 Jul 14]. Available from: https://ec.europa.eu/health/documents/community-register/2014/20140918129550/anx_129550_en.pdf
   Google Scholar
• Fineman MS , Cirincione BB , Maggs D , et al. GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes Obes Metab. 2012;14(8):675–688.
   PubMed Web of Science ®Google Scholar
• Becker RH , Stechl J , Msihid J , et al. Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes–a study in both people with type 2 diabetes and healthy subjects. Diabetes Obes Metab. 2014;16(9):793–800.
   PubMed Web of Science ®Google Scholar
• Meier JJ , Rosenstock J , Hincelin-Méry A , et al. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care. 2015;38(7):1263–1273.
   PubMed Web of Science ®Google Scholar
• Jin SM , Kim JH , Min KW , et al. Basal-prandial versus premixed insulin in patients with type 2 diabetes requiring insulin intensification after basal insulin optimization: a 24-week randomized non-inferiority trial. J Diabetes. 2016;8(3):405–413.
   PubMed Web of Science ®Google Scholar
• Vora J , Cohen N , Evans M , et al. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape). Diabetes Obes Metab. 2015;17(12):1133–1141.
   PubMed Web of Science ®Google Scholar
• Fulcher GR , Christiansen JS , Bantwal G , et al.; BOOST: Intensify Premix I Investigators . Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial. Diabetes Care. 2014;37(8):2084–2090.
   PubMed Web of Science ®Google Scholar
• Eng C , Kramer CK , Zinman B , et al. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 2014;384(9961):2228–2234.
   PubMed Web of Science ®Google Scholar
• Diamant M , Nauck MA , Shaginian R , et al.; 4B Study Group . Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care. 2014;37(10):2763–2773.
   PubMed Web of Science ®Google Scholar
• Rosenstock J , Guerci B , Hanefeld M , et al.; GetGoal Duo-2 Trial Investigators . Prandial options to advance basal insulin glargine therapy: testing lixisenatide plus basal insulin versus insulin glulisine either as basal-plus or basal-bolus in type 2 diabetes: the GetGoal Duo-2 trial. Diabetes Care. 2016;39(8):1318–1328.
   PubMed Web of Science ®Google Scholar
• Aroda VR , Rosenstock J , Wysham C , et al.; LixiLan-L Trial Investigators . Efficacy and safety of lixilan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: the LixiLan-L randomized trial. Diabetes Care. 2016;39(11):1972–1980.
   PubMed Web of Science ®Google Scholar
• Rosenstock J , Aronson R , Grunberger G , et al.; LixiLan-O Trial Investigators . Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O randomized trial. Diabetes Care. 2016;39(11):2026–2035.
   PubMed Web of Science ®Google Scholar
• Wysham C , Bonadonna RC , Aroda VR , et al.; LixiLan-L trial investigators . Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial. Diabetes Obes Metab. 2017;19(10):1408–1415.
   PubMed Web of Science ®Google Scholar
• Gough SC , Bode B , Woo V , et al.; NN9068-3697 (DUAL-I) trial investigators , Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2(11):885–893.
   PubMed Web of Science ®Google Scholar
• Buse JB , Vilsbøll T , Thurman J , et al.; NN9068-3912 (DUAL-II) Trial Investigators , Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care. 2014;37(11):2926–2933.
   PubMed Web of Science ®Google Scholar
• Linjawi S , Bode BW , Chaykin LB , et al. The efficacy of IDegLira (insulin degludec/liraglutide combination) in adults with type 2 diabetes inadequately controlled with a glp-1 receptor agonist and oral therapy: DUAL III randomized clinical trial. Diabetes Ther. 2017;8(1):101–114.
   PubMed Web of Science ®Google Scholar
• Lingvay I , Manghi FP , García-Hernández P , et al. Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes. The DUAL V randomized clinical trial. JAMA. 2016;315(9):898–907.
   PubMed Web of Science ®Google Scholar
• Rodbard HW , Bode BW , Harris SB , et al.; Dual Action of Liraglutide and insulin degludec (DUAL) IV trial investigators , Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial. Diabet Med. 2017;34(2):189–196.
   PubMed Web of Science ®Google Scholar
• de Vries ST , Keers JC , Visser R , et al. Medication beliefs, treatment complexity, and non-adherence to different drug classes in patients with type 2 diabetes. J Psychosom Res. 2014;76(2):134–138.
   PubMed Web of Science ®Google Scholar
• Unger J . Insulin initiation and intensification in patients with T2DM for the primary care physician. Diabetes Metab Syndr Obes. 2011;4:253–261.
   PubMedGoogle Scholar